Icon

RYTARY (nda203312)- (23.75MG;95MG,36.25MG;145MG,48.75MG;195MG,61.25MG;245MG)

CARBIDOPA; LEVODOPA IMPAX
23.75MG;95MG,36.25MG;145MG,48.75MG;195MG,61.25MG;245MG
Yes Yes
2028-Dec-26 Expired
None None
None No
RYTARY is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
0 2 0
Total Other Developers 24
Drugs with Suitability No
23.75MG;95MG ** ** Up - -
36.25MG;145MG ** ** Up - -
48.75MG;195MG ** ** Up - -
61.25MG;245MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.